GLP-1 Drugs Show Promise in Addiction Treatment
Analysis based on 21 articles · First reported Mar 04, 2026 · Last updated Mar 15, 2026
The study's findings suggest a significant expansion of the addressable market for GLP-1 drugs like Novo Nordisk===Semaglutide and Eli Lilly and Company===Tirzepatide, potentially boosting the stock prices of their manufacturers, Novo Nordisk and Eli Lilly and Company. This could lead to increased investment in pharmaceutical companies developing similar treatments for substance use disorders.
A large-scale observational study, published in The BMJ and led by Ziyad Al-Aly of the United States===VA St. Louis Health Care System, found that GLP-1 drugs such as Novo Nordisk===Semaglutide and Eli Lilly and Company===Tirzepatide may help prevent multiple substance use disorders and reduce associated harms. The analysis of over 600,000 U.S. Veterans Affairs patients with diabetes showed that those treated with GLP-1s had significantly lower risks of developing addictions to alcohol, nicotine, cocaine, cannabis, and opioids. For individuals already addicted, GLP-1 use was linked to reduced hospitalizations, overdoses, and deaths. While the study suggests a mechanism involving the brain's reward pathways, further randomized controlled clinical trials are needed to confirm these findings and justify prescribing GLP-1 drugs specifically for addiction treatment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard